Skip to main content

Advertisement

Log in

Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Background

Sarcomatoid renal cell carcinoma (sRCC) is a rare histological subtype that is associated with unfavorable prognosis. We sought to examine the effect of sRCC on cancer-specific mortality (CSM) relative to clear cell renal cell carcinoma (ccRCC), after adjusting for other variables, as well as other-cause mortality (OCM).

Methods

We relied on the Surveillance, Epidemiology, and End Results–Medicare database from 2000 to 2009 to identify a cohort of 7916 patients with either sRCC (n = 234) or ccRCC (n = 7682) who received surgery as primary treatment. Patient, tumor, and treatment characteristics were evaluated. Then, 5-year smoothed Poisson regression CSM and OCM estimates were generated for stage-by-stage comparisons between sRCC and ccRCC. A multivariable competing-risks regression model predicting CSM and adjusting for several patient and tumor characteristics, as well as OCM, was finally fitted.

Results

Compared to ccRCC patients, sRCC patients had more advanced and more aggressive disease at diagnosis. Specifically, 48 and 7 % of sRCC and ccRCC patients presented with stage IV disease, respectively (p < 0.001). Overall, 5-year CSM and OCM estimates were 67 and 17 % for sRCC patients and 14 and 19 % for ccRCC patients. In stage-by-stage analyses, sRCC was invariably associated with worse CSM. After adjusting for several characteristics as well as OCM, sRCC was associated with a 3.2 higher risk of CSM compared with ccRCC.

Conclusions

Patients with sRCC are present with more advanced disease. Moreover, sRCC is associated with a higher rate of CSM, even after adjusting for several characteristics and OCM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2014) Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer. doi:10.1016/j.clgc.2014.08.011

    PubMed  Google Scholar 

  2. Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC, Costello BA (2015) A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int 115(3):405–411. doi:10.1111/bju.12781

    Article  PubMed  Google Scholar 

  3. Brookman-May S, May M, Shariat SF, Zigeuner R, Chromecki T, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Feciche B, Coman I, Truss M, Pahernik S, Wirth MP, Zastrow S, Dalpiaz O, Fenske F, Waidelich R, Stief C, Gunia S, Members of the CP (2013) Prognostic effect of sarcomatoid dedifferentiation in patients with surgically treated renal cell carcinoma: a matched-pair analysis. Clin Genitourin Cancer 11(4):465–470. doi:10.1016/j.clgc.2013.04.026

    Article  PubMed  Google Scholar 

  4. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB (2001) Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25(3):275–284

    Article  PubMed  Google Scholar 

  5. Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL (2002) Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167(1):65–70

    Article  PubMed  Google Scholar 

  6. Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS (2012) Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int 109(11):1600–1606. doi:10.1111/j.1464-410X.2011.10785.x

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ (2014) Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. doi:10.1016/j.clgc.2014.12.001

    Google Scholar 

  8. Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP, Koppie TM (2012) Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 188(2):391–397. doi:10.1016/j.juro.2012.04.006

    Article  PubMed  PubMed Central  Google Scholar 

  9. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3-18. doi:10.1097/01.MLR.0000020942.47004.03

    PubMed  Google Scholar 

  10. Miller DC, Saigal CS, Warren JL, Leventhal M, Deapen D, Banerjee M, Lai J, Hanley J, Litwin MS (2009) External validation of a claims-based algorithm for classifying kidney-cancer surgeries. BMC Health Serv Res 9:92. doi:10.1186/1472-6963-9-92

    Article  PubMed  PubMed Central  Google Scholar 

  11. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258–1267. doi:10.1016/s0895-4356(00)00256-0

    Article  CAS  PubMed  Google Scholar 

  12. Sun M, Abdollah F, Liberman D, Abdo A, Thuret R, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI (2011) Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis. Cancer 117(18):4277–4285. doi:10.1002/cncr.25969

    Article  PubMed  Google Scholar 

  13. Sun M, Lughezzani G, Jeldres C, Isbarn H, Shariat SF, Arjane P, Widmer H, Pharand D, Latour M, Perrotte P, Patard JJ, Karakiewicz PI (2009) A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. Eur Urol 56(5):775–781. doi:10.1016/j.eururo.2009.06.008

    Article  PubMed  Google Scholar 

  14. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer (2014) 1–50. http://www.nccn.org

  15. http://www.rstudio.com (2014)

Download references

Authors’ contribution

Trudeau, Larcher, Karakiewicz contributed to protocol/project development. Trudeau, Larcher, Tian, Sun, Karakiewicz were involved in data collection or management. Trudeau, Larcher, Tian, Karakiewicz analyzed the data. Trudeau, Larcher, Karakiewicz contributed to manuscript writing/editing. Boehm, Fossati, Dell’Oglio, Briganti, Shariat, Sosa, Karakiewicz critically revised the manuscript for important intellectual content. Sun and Karakiewicz are acknowledged for supervision.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vincent Trudeau.

Ethics declarations

Conflict of interest

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors declare no conflicts of interest in preparing this article.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 41 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trudeau, V., Larcher, A., Sun, M. et al. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. World J Urol 34, 1429–1436 (2016). https://doi.org/10.1007/s00345-016-1780-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-016-1780-z

Keywords

Navigation